Question 1

What is Anticoagulant Citrate Phosphate Dextrose Adenine used for?

Accepted Answer

Anticoagulant Citrate Phosphate Dextrose Adenine helps dissolve or prevent formation of calculi (stones).

Question 2

Is there a generic for Anticoagulant Citrate Phosphate Dextrose Adenine?

Accepted Answer

No. Anticoagulant Citrate Phosphate Dextrose Adenine is brand-only with no generic equivalents currently in market.

Question 3

How much does my plan pay for Anticoagulant Citrate Phosphate Dextrose Adenine?

Accepted Answer

NADAC pricing data not currently available for this drug.

Question 4

Is Anticoagulant Citrate Phosphate Dextrose Adenine on the FDA shortage list?

Accepted Answer

No. Anticoagulant Citrate Phosphate Dextrose Adenine is not currently on the FDA Drug Shortage Database.

Question 5

What drug class is Anticoagulant Citrate Phosphate Dextrose Adenine in?

Accepted Answer

Anticoagulant Citrate Phosphate Dextrose Adenine is in the Calculi Dissolution Agent class. See related drugs in this class at /class/calculi-dissolution-agent.

Question 6

What is the brand name for Anticoagulant Citrate Phosphate Dextrose Adenine?

Accepted Answer

Anticoagulant Citrate Phosphate Dextrose Adenine is sold under the brand name CPDA-1.

Question 7

Is CPDA-1 the same as Anticoagulant Citrate Phosphate Dextrose Adenine?

Accepted Answer

Yes. CPDA-1 is a brand name for Anticoagulant Citrate Phosphate Dextrose Adenine. The generic version is identical in active ingredient, dose, and FDA-approved indications. Pricing differs substantially: generic Anticoagulant Citrate Phosphate Dextrose Adenine typically prices well below brand CPDA-1.

Question 8

What can I switch to instead of Anticoagulant Citrate Phosphate Dextrose Adenine?

Accepted Answer

Same-class alternatives include: Anhydrous Citric Acid, Dextrose Monohydrate, and Trisodium Citrate, Anhydrous Citric Acid, Trisodium Citrate Dihydrate, Sodium Phosphate, Monobasic, Monohydrate, Dextrose Monohydrate, and Adenine, Anticoagulant Citrate Dextrose (Acd). Whether substitution is clinically appropriate depends on patient indication, dose schedule, and contraindications — that is a P&T committee decision. The federal data shows cost and competition; clinical equivalence is not asserted here.

Question 9

When was Anticoagulant Citrate Phosphate Dextrose Adenine first FDA approved?

Accepted Answer

Anticoagulant Citrate Phosphate Dextrose Adenine received its first FDA approval on 2007-03-01.

Anticoagulant Citrate Phosphate Dextrose Adenine (CPDA-1)

Questions a plan sponsor actually asks.

Related questions.

Same class. Different math.

Sources · every number above traces back.